A source tells CNBC that former President Bill Clinton received two drug-coated stents, called "Xience," made by Abbott Labs.
Washington’s new political reality has left the fate of comprehensive healthcare reform uncertain, but there’s still plenty Congress and the Obama administration can do to improve the American healthcare system, writes this CEO.
Lockstep with Boomer aging, established industries are about to grow exponentially, and new wealth will be created by enterprises yet to be conceived.
Suffice to say that diabetes is a huge and fast-growing problem and represents a huge and fast-growing drug and device market.
I’m kind of torn over the fact that I’ve decided I won’t be going to the annual American College of Cardiology meeting in Atlanta about a month from now.
If you're left-handed, bowl with your right, eat red licorice, but only on Sunday afternoons, are female under 24-and-a-half years old or male over 33-and-three-quarters and loved "Dances With Wolves," then our drug is now approved for you to take.
I don't buy into the silly conspiracy theories that global health authorities worked in cahoots with the big, bad drug companies to gin up a pandemic scare just to goose vaccine and flu drug sales. Try telling that to the family of someone who died from H1N1.
The big drug companies are all looking to increase their footprints in emerging markets like India. But a young Ph.D., top-talent employee at Bristol-Myers Squibb apparently wanted to plant the flag on his own in his native country.
Thirteen-grand a year. That's about how much Acorda Therapeutics says it'll charge for its newly approved drug Ampyra for multiple sclerosis.
Nearly every city and state wants biopharma. They fiercely compete for the relatively clean industry and the well-paid, highly educated jobs it brings.
For Roche/Genentech the timing could not be worse. At a time when cutting healthcare costs could still end up being put back on the frontburner in Washington comes a study showing how to possibly save a heckuva lot of money.
Three out of four prescriptions in the U.S. are filled with generics. But a new, albeit small, survey by a prominent generic drug industry analyst shows even the people filling those pill bottles have issues with generics.
Big pharma is in the middle of getting leaner and meaner. Most, if not all, of the majors are getting rid of employees. They need to cut costs to preserve profits in the face of tens of billions of dollars worth of brand-name drugs going generic and their pipelines not delivering enough to fill that void. It's a sad reality of the business.
Levinson has not had a big hit like "Rain Man" in quite awhile, but he will reportedly be taking on the topic of bigness in the new GlaxoSmithKline-funded documentary about obesity. GSK makes the over-the-counter diet drug Alli.
We're used to major corporations sponsoring big sporting events, but a non-profit like ASCO? Huh?
In a new survey 72 percent of smokers said they thought the use of the word "sucks" was appropriate or extremely appropriate in Glaxo's Nicorette ad campaign that I've been blogging about over the past several weeks.
Bristol-Myers Squibb headquarters have moved from New York City to Portland, Oregon and Genzyme’s from Cambridge, Massachusetts to Seattle. Not for real, but in the movie “Extraordinary Measures” that opens today. I got to see it last night at the New York premiere.
These have been sunny days for Merck. Setting aside today’s action, the stock’s been on a pretty good tear lately hitting levels not seen in nearly two years. But the sun isn’t shining everywhere within the company.
The Financial Industry Regulatory Authority, the stock markets' self-policing arm, is looking into trading in Vivus shares around the time it announced its positive late-stage test results on its diet drug, Qnexa.
The Chairman and CEO of Alkermes had the chutzpah to get on Twitter yesterday. And he apparently isn’t just there to be a voyeur and to keep an eye on what’s being said in the biopharma Twitterverse. Pops has already sent out at least a couple of tweets.